MRK · Merck & Co., Inc. · Earnings Call Transcripts & Audio
$146.23
-0.92 (-0.63%)
At close · Sep 18
Market Cap
$357.37B
Shares
2.47B
Merck & Co., Inc. Earnings Call Transcripts
Quarterly earnings calls for Merck & Co., Inc. (MRK), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲13.7%
$14.96B
$3.25B
'22 Q3
22-10-27
▲2.3%
$13.83B
$3.02B
'22 Q4
23-02-02
▼8.9%
$14.49B
$2.82B
'23 Q1
23-04-27
▲3%
$15.04B
−$5.97B
'23 Q2
23-08-01
▲6.7%
$15.96B
$4.75B
'23 Q3
23-10-26
▲5.8%
$14.63B
−$1.23B
'23 Q4
24-02-01
▲8.9%
$15.78B
$4.76B
'24 Q1
24-04-25
▲7.2%
$16.11B
$5.46B
'24 Q2
24-07-30
▲4.4%
$16.66B
$3.16B
'24 Q3
24-10-31
▲6.8%
$15.62B
$3.74B
'24 Q4
25-02-04
▼1.6%
$15.53B
$5.08B
'25 Q1
25-04-24
▼1.9%
$15.81B
$4.43B
'25 Q2
25-07-29
▲3.7%
$17.28B
$5.79B
'25 Q3
25-10-30
▲5%
$16.40B
$2.96B
'25 Q4
26-02-03
▲4.9%
$16.29B
−$4.24B
'26 Q1
26-04-30
LATEST
▲5.1%
$16.61B
−$1.33B
'26 Q2
26-08-04
Conference
Investor event
2026-09-14
Merck & Co., Inc. (MRK) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Merck & Co., Inc. (MRK) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Merck & Co., Inc. (MRK) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcript
Confident tone
Keytruda oncology franchise
PD-1 VEGF bispecific and TL1A strategy
Lipfendra oral PCSK9 launch
Revenue
$16.61B
▲ 5.1% YoY Diluted EPS
$-0.54
▼ 130.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-03
Merck & Co., Inc. (MRK) August 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
Merck & Co., Inc. (MRK) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Merck & Co., Inc. (MRK) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Investor Update
Investor event
2026-06-01
Merck & Co., Inc. (MRK) June 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Annual General Meeting
Investor event
2026-05-26
Merck & Co., Inc. (MRK) May 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Transcript
Confident tone
Oncology / KEYTRUDA
Pipeline and Phase III catalysts
Terns Pharmaceuticals / TERN-701 (CML)
Revenue
$16.29B
▲ 4.9% YoY Diluted EPS
$-1.72
▼ 185.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-03
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Confident tone
Long-term commercial opportunity / pipeline transformation
Business development and M&A
Ophthalmology / MK-3000
Revenue
$16.40B*
▲ 5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
Merck & Co., Inc. (MRK) January 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-30
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Positive tone
Pipeline and R&D progress
Keytruda franchise and QLEX launch
WINREVAIR and new product launches
Revenue
$17.28B
▲ 3.7% YoY Diluted EPS
$2.32
▲ 87.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Confident tone
Pipeline and R&D momentum
New product launches (WINREVAIR, CAPVAXIVE, ENFLONSIA)
Business development / Verona Pharma acquisition
Revenue
$15.81B
▼ 1.9% YoY Diluted EPS
$1.76
▼ 17.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Positive tone
GARDASIL China decline
Tariffs and global supply chain
BD strategy characterization
Revenue
$15.53B
▼ 1.6% YoY Diluted EPS
$2.01
▲ 7.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-04
Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript
Positive tone
GARDASIL China headwind
WINREVAIR launch and PAH opportunity
KEYTRUDA and oncology franchise
Revenue
$15.62B*
▲ 6.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Merck & Co., Inc. (MRK) Q3 2024 Earnings Call Transcript
Positive tone
GARDASIL China headwinds and inventory
KEYTRUDA oncology leadership
Vaccines pipeline (clesrovimab and others)
Revenue
$16.66B
▲ 4.4% YoY Diluted EPS
$1.24
▼ 33.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript
Confident tone
GARDASIL / HPV
WINREVAIR launch
Pipeline breadth and BD
Revenue
$16.11B
▲ 7.2% YoY Diluted EPS
$2.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript
Confident tone
Vaccines pipeline (HPV, pneumococcal)
KEYTRUDA growth
WINREVAIR launch (PAH)
Revenue
$15.78B
▲ 8.9% YoY Diluted EPS
$1.87
▲ 68.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-01
Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript
Confident tone
Pipeline diversification and late-stage catalysts
Vaccines portfolio including RSV and dengue
Keytruda momentum and oncology leadership
Revenue
$14.63B*
▲ 5.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript
Revenue
$15.96B
▲ 6.7% YoY Diluted EPS
$1.86
▲ 45.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Merck & Co., Inc. (MRK) Q2 2023 Earnings Call Transcript
Revenue
$15.04B
▲ 3% YoY Diluted EPS
$-2.35
▼ 251.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript
Revenue
$14.49B
▼ 8.9% YoY Diluted EPS
$1.11
▼ 34.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
Merck & Co., Inc. (MRK) Q4 2022 Earnings Call Transcript
Revenue
$13.83B*
▲ 2.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Merck & Co., Inc. (MRK) Q3 2022 Earnings Call Transcript
Revenue
$14.96B
▲ 13.7% YoY Diluted EPS
$1.28
▼ 28.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Merck & Co., Inc. (MRK) Q2 2022 Earnings Call Transcript
Revenue
$14.59B
▲ 28% YoY Diluted EPS
$1.55
▲ 154.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Merck & Co., Inc. (MRK) Q1 2022 Earnings Call Transcript
Revenue
$15.90B
▲ 49.6% YoY Diluted EPS
$1.70
▲ 36% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
Merck & Co., Inc. (MRK) Q4 2021 Earnings Call Transcript
Revenue
$13.52B*
▲ 47.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Merck & Co., Inc. (MRK) Q3 2021 Earnings Call Transcript
Revenue
$13.15B
▲ 20.4% YoY Diluted EPS
$1.80
▲ 55.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Merck & Co., Inc. (MRK) Q2 2021 Earnings Call Transcript
Revenue
$11.40B
▲ 21.9% YoY Diluted EPS
$0.61
▼ 48.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Merck & Co., Inc. (MRK) Q1 2021 Earnings Call Transcript
Revenue
$10.63B
▼ 11.9% YoY Diluted EPS
$1.25
▲ 4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-04
Merck & Co., Inc. (MRK) Q4 2020 Earnings Call Transcript
Revenue
$9.18B*
▲ 121.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Merck & Co., Inc. (MRK) Q3 2020 Earnings Call Transcript
Revenue
$10.93B
▼ 11.8% YoY Diluted EPS
$1.16
▲ 64.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Merck & Co., Inc. (MRK) Q2 2020 Earnings Call Transcript
Revenue
$9.35B
▼ 20.5% YoY Diluted EPS
$1.18
▲ 20.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-28
Merck & Co., Inc. (MRK) Q1 2020 Earnings Call Transcript
Revenue
$12.06B
▲ 11.5% YoY Diluted EPS
$1.20
▲ 12.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-05
Merck & Co., Inc. (MRK) Q4 2019 Earnings Call
Revenue
$4.15B*
▼ 62.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–36 of 36 earnings calls
Key facts
CIK
310158
CUSIP
58933Y105
13F (30d)
128 filings
62 filers
Visit website
Investor relations